Do Fibroblast Growth Factor Receptor (FGFR) 2 and 3 Proteins Play a Role in the Prognosis of Invasive Urothelial Bladder Carcinoma?

Abstract

Background & Objective: Bladder carcinoma ranks second in prevalence among males in Egypt. As a family of tyrosine kinases, fibroblast growth factor receptor (FGFR) dysregulation has been linked to some malignancies in humans. The aim of this study is to analyze the clinicopathological data of patients while investigating FGFR2 and FGFR3 immunohistochemical expression in invasive urothelial bladder carcinoma.Methods: This retrospective cross-sectional study included 60 invasive urothelial carcinoma (UC) cases in the Pathology department, Faculty of Medicine, Menoufia University, from 2009 to 2020. All biopsies were stained for FGFR2 and FGFR3 antibodies. Complete clinical data were available for 44 patients treated and followed in clinical oncology and nuclear medicine departments.Results: Advanced stage and high grade are significantly correlated with FGFR2 positivity (P=0.048 and 0.044, respectively). Cases presented with Perineural invasion showed a higher percentage of FGFR2 (P=0.023). There is a significant indirect linear correlation between FGFR3 expression and lymph node positivity (r= -0.265, P=0.041).Conclusion: High FGFR2 expression was associated with poor prognostic parameters, while high FGFR3 expression was associated with good prognostic parameters, and this might highlight the importance of FGFR-targeted therapy as FGFR2 antagonist and FGFR3 agonist for the treatment of urothelial carcinoma patients.